These results suggest that for patients already receiving a GLP-1 RA who require additional treatment for glycaemic control, a switch to semaglutide could provide HbA1c and weight benefits without the need for more frequent administration
Regular laboratory monitoring typically includes HbA1c every 3 months, lipid panels, kidney function tests, and liver enzymes as clinically indicated
Semaglutide, retailed as Ozempic and Wegovy, is a GLP- 1 receptor agonist
Ongoing Care After the first visit, ongoing care runs through portal messaging, with one required video visit every three months to maintain the prescription and titrate up if needed
The glucagon receptor influences energy balance and fat metabolism
However, by slightly altering the chemical structure of this nutrient (adding the acetyl group), it can cross the blood-brain barrier and function to support both brain health and energy production